HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarins

This article was originally published in The Rose Sheet

Executive Summary

David Yurman beauty and fragrance products will launch under a partnership between the fine jewelry company and Clarins Groupe USA, French beauty firm announces Oct. 5. Items will be positioned as prestige offerings, with the first fragrance launching principally in the U.S. and Canada, company says. Yurman's "distinct identity and strong brand values" make it the "ideal platform for the launch of unique fragrances," Clarins notes. The jewelry firm adds the partnership is a good fit due to the companies' shared commitment to maintaining brand integrity. The deal is the latest in a string of luxury fragrance partnerships, including BeautyBank and bag designer Coach and Inter Parfums and fine jewelry marketer Van Cleef & Arpels (1"The Rose Sheet" Sept. 25, 2006, Marketing in Brief and 2"The Rose Sheet" Oct. 9, 2006, In Brief)...

You may also be interested in...



Marketing In Brief

BeautyBank: Coach fragrances and complementary products will debut under a partnership between the designer accessories brand and BeautyBank, the Estee Lauder division announces Sept. 22. Fragrances will embody the "many personalities of the Coach woman," with the first scent slated to launch in Spring 2007, positioned as a fresh and sophisticated offering, according to Coach. The agreement allows Coach to enter an "entirely new" product category under the belief that "fragrance will provide additional reasons for our customers to visit and purchase in Coach stores," firm notes...

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

UsernamePublicRestriction

Register

RS014276

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel